Century Therapeutics details CEO Flores' severance and CFO Diem's compensation

Century Therapeutics, Inc.

Flores receives 12 months base salary severance, COBRA reimbursement, and extended option exercise to 3 years.
80,100 unvested shares of restricted stock fully vest after 6-month advisory period.
CFO Diem's base salary increased to $500,000 with 45% bonus target.
Diem receives $500,000 RSU grant vesting 50% Nov 2023 and rest by Nov 2024 or performance milestone.
Separation agreement includes non-disparagement and cooperation clauses.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Osvaldo Flores

President and Chief Executive Officer

IPSC · Century Therapeutics, Inc.

Effective: 2023-04-11
Filed: May 5, 2023, 7:59 PM ET

Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.

Appointed

Michael Diem

Chief Financial Officer

IPSC · Century Therapeutics, Inc.

Effective: 2023-04-11
Filed: May 5, 2023, 7:59 PM ET

On April 11, 2023, the Board promoted Dr. Michael Diem to Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Osvaldo Flores departed as President and Chief Executive Officer at Century Therapeutics, Inc..

Action: stepped down
Role: President and Chief Executive Officer

Exact text from the filing

Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Diem was appointed as Chief Financial Officer at Century Therapeutics, Inc..

Action: promoted
Role: Chief Financial Officer

Exact text from the filing

On April 11, 2023, the Board promoted Dr. Michael Diem to Chief Financial Officer.

View on SEC.gov

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-056605

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.